Drug · DIN 02561514
BLEXTEN
Authorized, not yet reported as sold
Authorized for sale in Canada; the company has not yet told Health Canada that it is on the market.
Status Approved since October 1, 2025.
- Drug Identification Number (DIN)
- 02561514
- Company (DIN owner)
- Aralez Pharmaceuticals Canada Inc.Toronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Solution
- Route
- Ophthalmic
- Therapeutic class (ATC)
- Bilastine S01GX13
- Class
- Human
- Record last updated
- November 13, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| BILASTINE | 6 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 1, 2025: NOC 36097Supplement to a New Drug Submission (SNDS) · Addition of new indication: the treatment of ocular signs and symptoms of seasonal and perennial allergic conjunctivitis in adults. Addition of new route of administration: Ophthalmic. Addition of new dosage form: Ophthalmic solution. New package labels. New package insert
Other DINs named BLEXTEN
- DIN 02454130 · Marketed
- DIN 02519011 · Marketed
- DIN 02519038 · Marketed